secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bicara Therapeutics Inc. (BCAX)
CIK:        0002023658
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0002023658-25-000034
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicara Therapeutics Q1 net loss $36.8M; cash $462M; ASCO data update planned
----------------------------------------------------------------------------

- Cash and cash equivalents of $462.1M as of March 31, 2025, expected to fund operations into H1 2029.
- Net loss of $36.8M in Q1 2025, versus $12.5M in Q1 2024; R&D expenses rose to $34.3M.
- Updated Phase 1/1b data for ficerafusp alfa in 1L R/M HNSCC to be presented at ASCO 2025 (June 1).
- cSCC monotherapy expansion cohort showed ORR of 30.4% and median PFS of 7.0 months at AACR.
- Pivotal Phase 2/3 FORTIFI-HN01 trial enrolling; additional expansion cohorts ongoing or planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023658/000202365825000034/0002023658-25-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023658/000202365825000034/bcax-20250513.htm
  HTML page:      https://secwatch.observer/filing/0002023658-25-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer